Meeting
2018 Gastrointestinal Cancers Symposium
Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
Authors
J. Randolph Hecht
UCLA David Geffen School of Medicine, Los Angeles, CA
J. Randolph Hecht , Aung Naing , Gerald Steven Falchook , Manish R. Patel , Jeffrey R. Infante , Raid Aljumaily , Deborah Jean Lee Wong , Karen A. Autio , Zev A. Wainberg , Milind M. Javle , Johanna C. Bendell , Shubham Pant , Annie Hung , Peter Van Vlasselaer , Martin Oft , Kyriakos P. Papadopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02009449
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 374)
DOI
10.1200/JCO.2018.36.4_suppl.374
Abstract #
374
Poster Bd #
H11
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
First Author: J. Randolph Hecht
Poster
2017 ASCO Annual Meeting
PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA‑4 refractory melanoma.
First Author: Aung Naing
Poster
2016 ASCO Annual Meeting
Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer.
First Author: Kyriakos P. Papadopoulos
Poster
2023 ASCO Annual Meeting
Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study.
First Author: Hans Prenen